

Outcome of patients with peritoneal metastasis from ovarian cancer treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

Foslund, Ingrid Terese; Von Magius, Sahra Aisha Vinholt; Ainsworth, Alan Patrick; Detlefsen, Sönke; Fristrup, Claus Wilki; Knudsen, Anja Oer; Mortensen, Michael Bau; Tarpgaard, Line Schmidt; Jochumsen, Kirsten Marie; Graversen, Martin

Published in:
Pleura and Peritoneum

DOI:
10.1515/pp-2023-0049

Publication date:
2024

Document version:
Final published version

Document license:
CC BY

Citation for pulished version (APA):
Foslund, I. T., Von Magius, S. A. V., Ainsworth, A. P., Detlefsen, S., Fristrup, C. W., Knudsen, A. O., Mortensen, M. B., Tarpgaard, L. S., Jochumsen, K. M., & Graversen, M. (2024). Outcome of patients with peritoneal metastasis from ovarian cancer treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC). *Pleura and Peritoneum*, 9(2), 69-77. <https://doi.org/10.1515/pp-2023-0049>

Go to publication entry in University of Southern Denmark's Research Portal

Terms of use

This work is brought to you by the University of Southern Denmark.
Unless otherwise specified it has been shared according to the terms for self-archiving.
If no other license is stated, these terms apply:

- You may download this work for personal use only.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying this open access version

If you believe that this document breaches copyright please contact us providing details and we will investigate your claim.
Please direct all enquiries to puresupport@bib.sdu.dk

Ingrid Terese Foslund*, Sahra Aisha Vinholt von Magius, Alan Patrick Ainsworth, Sönke Detlefsen, Claus Wilki Frstrup, Anja Oer Knudsen, Michael Bau Mortensen, Line Schmidt Tarpgaard, Kirsten Marie Jochumsen and Martin Graversen

Outcome of patients with peritoneal metastasis from ovarian cancer treated with Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

<https://doi.org/10.1515/pp-2023-0049>

Received November 23, 2023; accepted May 13, 2024;

published online June 10, 2024

Abstract

Objectives: There are few data on Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin (PIPAC C/D) in women with primary unresectable or recurrent platinum-resistant peritoneal metastasis (PM) from ovarian cancer (OC). We evaluated survival, histological and cytological response, Quality of Life (QoL) and toxicity after PIPAC C/D in these patients.

Methods: Retrospective analysis of patients from the prospective PIPAC-OPC1 and -OPC2 studies. The histological response was evaluated by the Peritoneal Regression Grading Score (PRGS). QoL questionnaires were collected at baseline and after third PIPAC or 60 days. Adverse events were collected until 30 days after the last PIPAC. Demographic and survival data were analysed based on intention to treat. Response, QoL and toxicity were analysed per protocol (≥ 1 PIPAC).

Results: Twenty-nine patients were included. Five patients (17 %) were non-accessible at PIPAC 1. One patient was excluded due to liver metastases at PIPAC 1. Thus, 23 patients had 76 PIPACs (median 2, range 1–12). Median overall survival was 8.2 months (95 % CI 4.4–10.3) from PIPAC 1. Biopsy data were available for 22 patients, and seven (32 %) patients had a major/complete histological response ($PRGS \leq 2$) at PIPAC 3. No cytological conversions were registered. Symptoms and function scores worsened, while emotional scores improved. Three patients had severe adverse reactions (two ileus, one pulmonary embolism); no life-threatening reactions or treatment-related mortality was observed.

Conclusions: PIPAC C/D was feasible and induced histological regression in a substantial proportion of patients with platinum-resistant PM from OC. Larger studies are needed to evaluate impact on survival.

Keywords: Ovarian Cancer; Peritoneal Metastasis; Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC); Peritoneal Regression Grading Score (PRGS); Quality of Life (QoL)

Ingrid Terese Foslund and Sahra Aisha Vinholt von Magius share first authorship.

***Corresponding author: Ingrid Terese Foslund**, MD, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; and Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark, E-mail: ingridfoslund@outlook.com

Sahra Aisha Vinholt von Magius, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; and Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark

Alan Patrick Ainsworth and Michael Bau Mortensen, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark; and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark. <https://orcid.org/0000-0002-7270-5005> (M.B. Mortensen)

Sönke Detlefsen, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; and Department of Pathology, Odense University Hospital, Odense, Denmark. <https://orcid.org/0000-0002-9466-2333>

Claus Wilki Frstrup, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; and Department of Surgery, Odense University Hospital, Odense, Denmark

Anja Oer Knudsen, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; and Department of Oncology, Odense University Hospital, Odense, Denmark

Line Schmidt Tarpgaard, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; and Department of Oncology, Odense University Hospital, Odense, Denmark

Kirsten Marie Jochumsen, Department of Obstetrics and Gynaecology, Odense University Hospital, Odense, Denmark; and Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark

Martin Graversen, Odense PIPAC Centre, Odense University Hospital, Odense, Denmark; Department of Surgery, Odense University Hospital, Odense, Denmark; Department of Clinical Research, Faculty of Health Sciences, University of Southern Denmark, Odense, Denmark; and OPEN – Open Patient Data Explorative Network, Odense University Hospital, Odense, Denmark

Introduction

Ovarian cancer (OC) is the eighth most common malignancy and the fifth most common cause of cancer mortality in women worldwide [1–3]. According to the Danish cancer registry, the age-adjusted incidence rate is 14 per 100,000 women, including tubarian, ovarian and primary peritoneal cancer [4]. More than 90 % have malignant epithelial type dominated by high-grade serous adenocarcinoma. Eighty percent are diagnosed in International Federation of Gynaecology and Obstetrics (FIGO)-stage III–IV, where the 5-year survival is only 25–36 % [5, 6]. Despite complete primary or interval debulking surgery including platinum- and taxane-based chemotherapy, most patients suffer from recurrent disease [7–9]. These patients may benefit from reintroduced platinum- and taxane-based chemotherapy with a median survival (mOS) of 30 months [10, 11]. Still, there is no standard treatment in patients with platinum-resistant OC, even if randomized controlled trials in selected patients show a median survival of 9–12 months after treatment with single agent chemo- or immunotherapy [12, 13].

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC) with cisplatin and doxorubicin (C/D) was introduced a decade ago as an intraperitoneal drug delivery system in patients with peritoneal metastasis (PM) [14, 15]. Tempfer et al. showed a histology-based response rate of 76 % and a mOS of 14.1 months after the first PIPAC C/D in 50 women with recurrent platinum-resistant OC with isolated PM [16]. The feasibility and safety of PIPAC has been shown in patients with PM from various primary tumours, and the procedure may be performed in the outpatient clinic [17, 18]. In a randomized controlled trial, Somashekhar et al. is currently investigating efficacy in 100 women with recurrent platinum-resistant ovarian cancer randomly allocated to PIPAC C/D or systemic chemotherapy [19]. Further, the PARROT trial showed that PIPAC C/D was feasible and showed a clinical benefit rate in 33/40 (82 %) women with recurrent platinum-resistant ovarian cancer [20]. Still, more treatment specific data on PIPAC in women with primary unresectable or recurrent platinum resistant OC are needed before evaluating efficacy in large randomized clinical trials.

Based on data from two prospective trials, this study aimed to report survival, histological/cytological response, Quality of Life (QoL) and toxicity in patients with PM from primary unresectable or recurrent platinum-resistant tubarian, ovarian or primary peritoneal high-grade serous adenocarcinoma.

Materials and methods

This is a retrospective subgroup analysis of patients with primary unresectable or recurrent platinum-resistant PM from OC, who were included in the prospective PIPAC-OPC1 and -OPC2 trials at Odense PIPAC Centre, Denmark from 2015 to 2022. The inclusion and exclusion criteria have been described previously [21, 22]. These criteria were identical apart from the acceptance of Eastern Cooperative Oncology Group (ECOG) performance score (PS) 0–2 in PIPAC-OPC1, whereas only patients with PS 0–1 were accepted in PIPAC-OPC2. Further, patients with isolated PM were included in PIPAC-OPC1, while one extraperitoneal metastasis was allowed in PIPAC-OPC2.

Patients were discussed at a dedicated multidisciplinary tumour (MDT) conference prior to inclusion. If eligible, they were scheduled for a series of three PIPAC C/Ds at an interval of 4 to 6 weeks. The response to treatment was evaluated by histology of peritoneal quadrant biopsies (QBs), peritoneal lavage or ascites cytology, a computed tomography (CT) and onset or disappearance of symptoms. Patients were again discussed at the MDT conference and continued PIPAC if these endpoints did not lead to a conclusion of disease progression.

Pressurized IntraPeritoneal Aerosol Chemotherapy (PIPAC)

The PIPAC C/D procedure has been described previously [15, 21]. In selected cases, patients were treated with electrostatic precipitation PIPAC (ePIPAC) according to an approved amendment to the PIPAC-OPC2 study [23].

Outcomes

Survival

Survival was calculated from the date of PIPAC 1 in the intention to treat population.

Histological/cytological response

The QBs were evaluated according to the four-tiered Peritoneal Regression Grading Score (PRGS) [24]. In short, PRGS 1 denotes a complete histological response, PRGS 2 a major histological response, PRGS 3 a minor histological response and PRGS 4 no histological response. The PRGS was reported

separately for each QB and as a mean value, for all biopsies from a given QB set. Up-front immunohistochemical staining for the epithelial cell adhesion molecule (EpCAM), a marker with high sensitivity and specificity for PM, was used in addition to conventional H&E staining of the biopsies, as described previously [21, 24–30]. The mean PRGS was calculated as the average of all QBs obtained prior to a given PIPAC C/D. A histology-based response to PIPAC was defined as a mean PRGS \leq 2 at PIPAC 3 (unless PRGS \leq 2 already at PIPAC 1) or an absolute mean PRGS reduction \geq 1.0 from PIPAC 1 to PIPAC 3 [22, 26]. Peritoneal lavage fluid was aided by immunocytochemical staining on demand and graded as malignant cells, cells suspicious of malignancy, atypical cells, no malignant cells and other. A cytological response/progression was defined as conversion from malignant or suspicious cells to non-malignant cells and vice versa. Histological and cytological analyses were performed by the same pathologist to avoid inter-observer variability.

Quality of life

The European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) was collected at baseline and after 60 days (OPC1 study) or after the third PIPAC (OPC2 study) [31].

Toxicity

A study nurse collected data on 30 days adverse events (Common Terminology Criteria for Adverse Events (CTCAE) version 4.0) and surgical complications according to the Clavien–Dindo classification [32, 33]. The causality to treatment was evaluated by the principal investigator and sponsor. Adverse events that were probably or certainly related to treatment were reported. To avoid double registration, surgical complications were exclusively defined as postoperative bleeding, intra-abdominal abscess or bowel perforation.

Statistics

Patients assigned to PIPAC were defined as the intention to treat (ITT) population, and baseline characteristics and survival data were analysed according to ITT. Patients who completed \geq 1 PIPAC were included in the per protocol (PP) population. Treatment-related data including response, QoL and toxicity were analysed PP. Values were given as means or medians where appropriate. Categorical data

were specified with 95 % confidence intervals (95 % CI), and comparisons were performed using parametric or non-parametric tests after test for normal distribution. p-Values were two-tailed, and a p-value of 0.05 was considered statistically significant. Survival was calculated from date of PIPAC 1 and modelled in Kaplan–Meier survival curves.

Ethical clearance

This study is a subgroup analysis of patients who consented to the prospective PIPAC-OPC1 and -OPC2 studies [21, 22]. These studies were conducted according to the Helsinki declaration.

Results

The PIPAC-OPC1 trial included 35 patients from March 2015 to October 2016, and the OPC2 trial (including the amendment on ePIPAC) included 143 patients from December 2016 to January 2022. Of these, 29 OC patients were eligible for the ITT analysis (Table 1 and Figure 1). The median (range) time from OC diagnosis to PIPAC 1 was 30 (3–131) months. Nineteen patients (66 %) had recurrence after complete or optimal debulking surgery. More than 1/3 of the patients had disease progression after first line single agent chemotherapy instituted after platinum resistancy, and none of the patients received synchronous systemic chemotherapy during or in between PIPAC. Three patients

Table 1: Baseline characteristics of ovarian cancer patients treated with Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin.

Number of included patients	29
Age, median years (range)	64 (42–77)
ECOG performance status 0, n (%)	8 (27.6)
ECOG performance status 1, n (%)	21 (72.4)
Primary unresectable ovarian cancer, n (%)	10 (34)
Platinum-resistant recurrent ovarian cancer, n (%)	19 (66)
Extraperitoneal metastasis at inclusion n (%)	3 (13)
Previous treatment	
Previous palliative chemotherapy, n (%)	29 (100)
Median lines of palliative chemotherapy (range)	2 (1–10)
One line	8 (28)
Two lines	10 (34)
>Two lines	11 (38)

ECOG, Eastern Cooperative Oncology Group; PIPAC, Pressurized IntraPeritoneal Aerosol Chemotherapy.




Figure 1: Flow chart of patient enrolment. C/D, cisplatin and doxorubicin; ITT, intention to treat; n, number of patients; OC, ovarian cancer; OPC, Odense PIPAC Center; PIPAC, Pressurized IntraPeritoneal Aerosol Chemotherapy; PM, peritoneal metastasis.

had extraperitoneal metastases at inclusion (two had supradiaphragmatic lymph node metastasis, one had lung metastasis). Five patients were excluded due to primary laparoscopic non access, and one was excluded due to the presence of liver metastases detected during standard laparoscopic ultrasound immediately prior to the PIPAC procedure. Ultimately, 23 patients (5 from PIPAC-OPC1 and 18

from PIPAC-OPC2) were included in the PP population, who had a total of 76 treatments (63 PIPACs and 13 ePIPACs, median 2, range 1–12).

The mean (SD) PIPAC procedure time was 86 (20) minutes, and 42 (55 %) treatments were performed in the outpatient clinic. The median (range) follow-up from PIPAC 1 was 18 (3–52) months.




Figure 2: Overall survival after Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin.

Survival

The mOS was 8.2 months (95 % CI 4.4–10.3) after PIPAC 1 (ITT) (Figure 2).

Histological/cytological response

Biopsy data were available in 22 patients. Two patients had a PRGS ≤ 2 at PIPAC 1, while 7/22 (32 %) patients had a major or complete histological response (mean PRGS ≤ 2) at PIPAC 3, whereas no cytological conversions were registered (Table 2).

Table 2: Response evaluation of patients treated with Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin.

	Histology		
	PIPAC 1	PIPAC 2	PIPAC 3
Number of patients with biopsy data	n=22	n=15	n=10
PRGS MEAN (SD)	2.86 (0.76)	2.19 (0.67)	1.98 (0.68)
MEAN PRGS 1 OR 2, n	2	7	7
PRGS MAX (SD)	3.22 (0.75)	2.60 (0.74)	2.40 (0.84)
MAX PRGS 1 OR 2, n	2	6	4
	Cytology		
	PIPAC 1	PIPAC 2	PIPAC 3
Number of patients with cytology data	n=21	n=15	n=10
Positive cytology	19	13	10
Cytological conversion	-	0	0

MAX, maximum; n, number of patients; PIPAC, Pressurized IntraPeritoneal Aerosol Chemotherapy; PRGS, Peritoneal Regression Grading Score; SD, standard deviation.

Quality of life

Twenty-seven (including all data from ITT population) and 10 questionnaires were collected at baseline and after treatment, respectively (Figure 3). Overall, patients reported more symptoms and decreasing function scores apart from improved emotional and unchanged cognitive function.

Toxicity

There was no treatment-related mortality and no life-threatening adverse reactions (Table 3). Three severe adverse reactions were recorded of which two patients had ileus (treated conservatively) and one patient had a pulmonary embolism. Pain, nausea and vomiting were the most common mild or moderate adverse reactions. No severe surgical complications were recorded, but we observed one case of wound dehiscence, one case of haematoma and three cases of fluid leakage from the port site scars.

Discussion

This retrospective analysis of prospectively collected data from 29 patients with primary unresectable or recurrent platinum-resistant PM from OC showed a mOS of 8.2 months from PIPAC 1. It also showed a major or complete histological response (PRGS ≤ 2) in 32 % of the patients at PIPAC 3 but no peritoneal cytology-based response. The QoL scores deteriorated slightly after PIPAC even though it was well tolerated with minimal toxicity.




Figure 3: Quality of Life scores at baseline and after Pressurized IntraPeritoneal Aerosol Chemotherapy with cisplatin and doxorubicin. EORTC QLQ-C30, The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire 30; n, number of patients; PIPAC, Pressurized IntraPeritoneal Aerosol Chemotherapy.

Table 3: Procedure related data.

Procedure related data									
Number of PIPAC treatments, median (range)									76, 2 (1–12)
Treatments performed with ePIPAC n (%)									13 (17)
Outpatient procedures, n (%)									42 (55)
Adverse reactions									
Grade	Pain	Obstipation	Diarrhoea	Ileus	Nausea	Vomiting	Urinary retention	Wound infection	Other ^a
1–2 n	43	15	4	0	33	21	6	4	11
3 n	0	0	0	2	0	0	0	0	1
4 n	0	0	0	0	0	0	0	0	0
30-day mortality	0	0	0	0	0	0	0	0	0
Surgical complications									
Grade	Bleeding		Abscess		Perforation		Other		
1–2 n	1		0		0		5		
≥3a n	0		0		0		0		

PIPAC, Pressurized IntraPeritoneal Aerosol Chemotherapy; SD, standard deviation. ^aGrade 1–2: one case of pneumonia, 10 cases of fatigue and sweating and one case of pulmonary embolism (grade 3).

We excluded five patients from the ITT population due to a non-accessible abdomen and one patient due to liver metastases at the index laparoscopic ultrasound. We, therefore, had a non-access rate of 17 %, which is in agreement with a recent review in which the primary and secondary non-access rates were between 0 and 17 % [18]. The non-access rate is also in agreement with Tempfer et al. and is arguably caused by the high rate of patients with adhesions due to previous primary or interval debulking surgery [16].

Survival of 8 months after PIPAC 1 is interesting in this group of patients with platinum-resistant disease. Tempfer et al. showed an even better mean survival of 331 days after PIPAC 1 in a prospective study of 53 women with PM from recurrent, platinum-resistant ovarian, tubarian or primary peritoneal cancer [16]. The difference in survival rates might be due to differences of the populations studied. One third of the patients in the present study were never resected, whereas all patients in the study by Tempfer et al. were amenable for primary/interval debulking. The AURELIA study showed a mOS of 16.6 months in platinum-resistant OC patients treated by a combination of chemotherapy and bevacizumab [34]. Importantly, the AURELIA study used strict inclusion criteria and, therefore, excluded patients who had more than two previous anticancer regimens or

who progressed during platinum-based treatment, which hinders comparison of survival rates. The recent PARROT trial investigated feasibility and radiological response to PIPAC C/D in 43 women with platinum-resistant recurrent ovarian cancer [20]. The authors reported a survival of 27 months, which is impressive. This survival, however, was computed from the date of recurrence imposing obvious lead-time bias. Further, the PARROT trial only included patients with recurrent disease who had a maximum of two lines of systemic chemotherapy, whereas our study included 11 patients (38 %) who had more than two lines of chemotherapy prior to PIPAC.

Seven of ten patients who completed three PIPACs had a major or complete histological response to treatment, which is encouraging. In comparison, no patients in the aforementioned PARROT trial showed response according to PRGS. Of note, it is difficult to deduce the impact and clinical consequences of the biopsy strategy in the PARROT trial where biopsies were taken after administration of chemotherapy [20]. Most centres recommend biopsies before administration of chemotherapy [22, 35]. Data on the prognostic impact of PRGS are still dubious, and some studies have considered response to PIPAC as any decrease in PRGS during treatment [21]. Also, the biopsy strategy during

response evaluation is not uniform, since some centres clips mark biopsy sites, while others biopsy new lesions at every PIPAC. Importantly, the recently published PIPAC-OPC2 study showed that a cut-off of mean PRGS \leq 2.0 or an absolute decrease of 1.0 from PIPAC 1 to 3 held positive prognostic value, which is also in accordance with the findings of Baake et al. [22, 36]. Further, the evaluation of PRGS is reproducible with a good to excellent inter-observer variability, and up-front immunohistochemistry can improve the reproducibility of the PRGS, particularly in less experienced observers [22, 25, 27, 37, 38].

We observed no cytology-based response from PIPAC 1 to 3. Cytology may be perceived as an adjunct to PRGS, especially regarding PM located to the visceral peritoneum, which is usually not biopsied. Still, the isolated sensitivity of conventional cytology is only 50–60%, and studies have indicated that peritoneal cytology holds no independent prognostic value unless combined with the maximum PRGS score [24, 30, 39]. The examination of ascites or peritoneal lavage fluid may still play a crucial role, but perhaps more comprehensive molecular analyses are required to fully utilize its potential impact.

QoL evaluations were based on data retrieved at dissimilar time points after PIPAC 3 or 60 days, which impose an obvious selection bias as it excludes data from previous dropped out patients. The changes were based on only two different measurements of QoL in a small group of 10 women, so no firm conclusions could be drawn.

The adverse events profile was acceptable with mainly mild to moderate abdominal pain, nausea and vomiting. Two severe reactions of ileus were seen, but they were treated conservatively. The adverse reactions were thus manageable, which is in agreement with previous reports of complications and toxicity [21]. No severe surgical complications were observed.

Conclusions from the present study are limited by its retrospective design. Although data were collected in two prospective trials, they were not designed to be incorporated in this subgroup analysis. The inclusion criteria differed between studies, and some procedures (17%) were completed with electrostatic precipitation, which might have altered the treatment efficacy. The PIPAC-OPC1 and -OPC2 studies accrued patients before the dose escalation study by Tempfer et al. in 2018 and, therefore, used cisplatin 7.5 mg/m² and doxorubicin 1.5 mg/m² [40]. From a methodological perspective, this should be considered a strength, but it might also preclude patients from a more effective treatment with higher doses of chemotherapy. No patients received bidirectional chemotherapy, which

should be considered a strength, since it allowed the assessment of PIPAC monotherapy. On the other hand, this study does not provide feasibility and safety data of PIPAC in combination with systemic chemotherapy, which must be further investigated in similar study populations.

The efficacy of PIPAC C/D in patients with PM from OC must be examined further in randomized controlled trials. It could be of relevance to stratify OC patients into subgroups based on prior treatments, including both surgery and chemotherapy to evaluate which patients are most susceptible to PIPAC. Further studies must also evaluate the optimal drugs and doses for patients with OC treated with PIPAC. Perhaps the use of PIPAC with paclitaxel could be an interesting alternative but must await a recommended phase II dose, which is currently being investigated [41].

Conclusions

In conclusion, PIPAC C/D was feasible and led to a major or complete histology-based response in a substantial proportion of patients with platinum-resistant OC. Randomized studies are warranted to show a potential survival benefit in patients with OC but also more prospective phase II studies that investigate the technical aspects of PIPAC such as optimal drugs, doses, pressure and diffusion time.

Acknowledgments: Ulla Krogstrup Tecedor, Research Nurse, Odense PIPAC Center, Department of Surgery, Odense University Hospital. Claire Gudex MD, MPH, MBChB, Associate professor Clinical Institute, University of Southern Denmark in Odense. Lector, KI, Odense University Hospital. Charlotte Leboeuf-Yde chiropractor, MPH, Ph.D. Department of Regional Health Research, Professor, Department Secretariat, University of Southern Denmark in Odense.

Research ethics: The ovarian cancer patients consented to the prospective PIPAC-OPC1 and -OPC2 studies. These studies were conducted according to the Helsinki declaration.

Informed consent: Informed consent was obtained from all individuals included in this study.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: The authors state no conflict of interest.

Research funding: None declared.

Data availability: The data from this study cannot be shared due to Danish legislation.

References

1. Armstrong DK, Alvarez RD, Bakkum-Gamez JN, Barroilhet L, Behbakht K, Berchuck A, et al. Ovarian cancer, version 2.2020, NCCN clinical practice guidelines in oncology. *J Natl Compr Cancer Netw* 2021; 19:191–226.
2. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2021. *CA A Cancer J Clin* 2021;71:7–33.
3. World Health Organization. Worldwide cancer data. World Health Organization; 2020. London. Available from: <https://www.wcrf.org/cancer-trends/worldwide-cancer-data/>. [Accessed 15 Dec 2022].
4. Nye Sundhedsdatastyrelsen. Kræfttilfælde i Danmark 2021. Copenhagen: Cancerregisteret: Sundhedsdatastyrelsen; 2023. https://sundhedsdatastyrelsen.dk/-/media/sds/filer/find-tal-og-analyser/sygdomme-og-behandlinger/kraeft/kraeft_nye_tilfaelde_aarsrapporter/kraefttilfaelde-2021.pdf.
5. Gruppe DGC. Ovariecancer – epidemiologi, arvelige faktorer, screening, sygdomsforløb, stadienddeling og overlevelse 2023. Available from: http://www.dgcg.dk/images/retningslinier/Ovariecancer/DGCG_epidemiologi_c_ovarii_v1.1_AdmGodk_3005224704.pdf [Accessed 15 Dec 2022].
6. Gruppe DGC. Ovariecancer – Patologi procedure for epithelial ovariecancer DGCG. 2022. Available from: http://www.dgcg.dk/images/retningslinier/Ovariecancer/DGCG_Patologiproc_epi_o_cancer_v.1.0_AdmGodk1705224621.pdf [Accessed 15 Dec 2022].
7. Hennessy BT, Coleman RL, Markman M. Ovarian cancer. *Lancet*. 2009; 374:1371–82.
8. Stewart L, Advanced Ovarian Cancer Trialists Group. Chemotherapy for advanced ovarian cancer. Advanced ovarian cancer trialists group. *Cochrane Database Syst Rev* 2000;25.01.1999:Cd001418.
9. Matulonis UA, Sood AK, Fallowfield L, Howitt BE, Sehouli J, Karlan BY. Ovarian cancer. *Nat Rev Dis Prim* 2016;2:16061.
10. Parmar MK, Ledermann JA, Colombo N, du Bois A, Delaloye JF, Kristensen GB, et al. Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial. *Lancet* 2003; 361:2099–106.
11. Kajiyama H, Shibata K, Mizuno M, Umezaki T, Suzuki S, Sekiya R, et al. Survival benefit of taxane plus platinum in recurrent ovarian cancer with non-clear cell, non-mucinous histology. *J Gynecol Oncol* 2014;25:43–50.
12. Hanker LC, Loibl S, Burchardi N, Pfisterer J, Meier W, Pujade-Lauraine E, et al. The impact of second to sixth line therapy on survival of relapsed ovarian cancer after primary taxane/platinum-based therapy. *Ann Oncol* 2012;23:2605–12.
13. Davis A, Tinker AV, Friedlander M. “Platinum resistant” ovarian cancer: what is it, who to treat and how to measure benefit? *Gynecol Oncol* 2014;133:624–31.
14. Solaß W, Hetzel A, Nadiradze G, Sagynaliev E, Reymond MA. Description of a novel approach for intraperitoneal drug delivery and the related device. *Surg Endosc* 2012;26:1849–55.
15. Solass W, Kerb R, Mürdter T, Giger-Pabst U, Strumberg D, Tempfer C, et al. Intraperitoneal chemotherapy of peritoneal carcinomatosis using pressurized aerosol as an alternative to liquid solution: first evidence for efficacy. *Ann Surg Oncol* 2014;21:553–9.
16. Tempfer CB, Winnekendonk G, Solass W, Horvat R, Giger-Pabst U, Zieren J, et al. Pressurized intraperitoneal aerosol chemotherapy in women with recurrent ovarian cancer: a phase 2 study. *Gynecol Oncol* 2015;137:223–8.
17. Graversen M, Lundell L, Fristrup C, Pfeiffer P, Mortensen MB. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) as an outpatient procedure. *Pleura Peritoneum* 2018;3:20180128.
18. Alyami M, Hübner M, Grass F, Bakrin N, Villeneuve L, Laplace N, et al. Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications. *Lancet Oncol* 2019;20: e368–77.
19. Somashekhar SP, Ashwin KR, Rauthan A, Rohit KC. Pressurized IntraPeritoneal Aerosol Chemotherapy vs. intravenous chemotherapy for unresectable peritoneal metastases secondary to platinum resistant ovarian cancer – study protocol for a randomized control trial. *Pleura Peritoneum* 2019;4:20180111.
20. Vizzielli G, Giudice MT, Nardelli F, Costantini B, Salutari V, Inzani FS, et al. Pressurized IntraPeritoneal aerosol chemotherapy (PIPAC) applied to platinum-resistant recurrence of ovarian tumor: a single-institution experience (ID: PARROT trial). *Ann Surg Oncol* 2024; 31:1207–16.
21. Graversen M, Detlefsen S, Bjerregaard JK, Fristrup CW, Pfeiffer P, Mortensen MB. Prospective, single-center implementation and response evaluation of pressurized intraperitoneal aerosol chemotherapy (PIPAC) for peritoneal metastasis. *Ther Adv Med Oncol* 2018;10:Article no. 1758835918777036.
22. Graversen M, Detlefsen S, Ainsworth AP, Fristrup CW, Knudsen AO, Pfeiffer P, et al. Treatment of peritoneal metastasis with pressurized intraperitoneal aerosol chemotherapy: results from the prospective PIPAC-OPC2 study. *Ann Surg Oncol* 2023;30:2634–44.
23. Graversen M, Detlefsen S, Ellebaek SB, Fristrup C, Pfeiffer P, Mortensen MB. Pressurized IntraPeritoneal Aerosol Chemotherapy with one minute of electrostatic precipitation (ePIPAC) is feasible, but the histological tumor response in peritoneal metastasis is insufficient. *Eur J Surg Oncol* 2020;46:155–9.
24. Solass W, Sempoux C, Detlefsen S, Carr NJ, Bibeau F. Peritoneal sampling and histological assessment of therapeutic response in peritoneal metastasis: proposal of the Peritoneal Regression Grading Score (PRGS). *Pleura Peritoneum* 2016;1:99–107.
25. Fallah M, Detlefsen S, Ainsworth AP, Fristrup CW, Mortensen MB, Pfeiffer P, et al. Importance of biopsy site selection for peritoneal regression grading score (PRGS) in peritoneal metastasis treated with repeated pressurized intraperitoneal aerosol chemotherapy (PIPAC). *Pleura Peritoneum* 2022;7:143–8.
26. Roensholdt S, Detlefsen S, Mortensen MB, Graversen M. Response evaluation in patients with peritoneal metastasis treated with pressurized IntraPeritoneal aerosol chemotherapy (PIPAC). *J Clin Med* 2023;12:1289.
27. Solass W, Sempoux C, Carr NJ, Bibeau F, Neureiter D, Jäger T, et al. Reproducibility of the peritoneal regression grading score for assessment of response to therapy in peritoneal metastasis. *Histopathology* 2019;74:1014–24.
28. Went PT, Meier S, Bundi M, Mirlacher M, Sauter G. Frequent EpCam protein expression in human carcinomas, et al. Frequent EpCam protein expression in human carcinomas. *Hum Pathol* 2004;35:122–8.
29. Ordóñez NG. Value of the MOC-31 monoclonal antibody in differentiating epithelial pleural mesothelioma from lung adenocarcinoma. *Hum Pathol* 1998;29:166–9.
30. Graversen M, Fristrup C, Kristensen TK, Larsen TR, Pfeiffer P, Mortensen MB, et al. Detection of free intraperitoneal tumour cells in peritoneal lavage fluid from patients with peritoneal metastasis before

- and after treatment with pressurized intraperitoneal aerosol chemotherapy (PIPAC). *J Clin Pathol* 2019;72:368–72.
31. Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. *J Natl Cancer Inst* 1993;85:365–76.
 32. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. *Ann Surg* 2004;240:205–13.
 33. Institute NC. Common Terminology criteria for adverse events (CTCAE) v4.0 ctep.cancer.gov/2010 [updated June 14 2010]. 2010. Available from: https://ctep.cancer.gov/protocoldevelopment/electronic_applications/ctc.htm#ctc_40 [Accessed 15 Dec 2022].
 34. Pujade-Lauraine E, Hilpert F, Weber B, Reuss A, Poveda A, Kristensen G, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. *J Clin Oncol* 2014;32:1302–8.
 35. Toussaint L, Teixeira Farinha H, Barras JL, Demartines N, Sempoux C, Hübner M. Histological regression of gastrointestinal peritoneal metastases after systemic chemotherapy. *Pleura Peritoneum* 2021;6: 113–19.
 36. Baake J, Nadiradze G, Archid R, Königsrainer A, Bösmüller H, Reymond M, et al. Peritoneal regression grading score (PRGS): first evidence for independent predictive and prognostic significance. *Pleura Peritoneum* 2023;8:55–63.
 37. Grass F, Vuagniaux A, Teixeira-Farinha H, Lehmann K, Demartines N, Hübner M. Systematic review of pressurized intraperitoneal aerosol chemotherapy for the treatment of advanced peritoneal carcinomatosis. *Br J Surg* 2017;104:669–78.
 38. Detlefsen S, Windedal T, Bibeau F, Bruhn LV, Carr N, Graverson M, et al. Role of immunohistochemistry for interobserver agreement of Peritoneal Regression Grading Score in peritoneal metastasis. *Hum Pathol* 2022;120:77–87.
 39. Benzerdjeb N, Durieux E, Tantot J, Isaac S, Fontaine J, Harou O, et al. Prognostic impact of combined progression index based on peritoneal grading regression score and peritoneal cytology in peritoneal metastasis. *Histopathology* 2020;77:548–59.
 40. Tempfer CB, Giger-Pabst U, Seebacher V, Petersen M, Dogan A, Rezniczek GA. A phase I, single-arm, open-label, dose escalation study of intraperitoneal cisplatin and doxorubicin in patients with recurrent ovarian cancer and peritoneal carcinomatosis. *Gynecol Oncol* 2018;150:23–30.
 41. Kim GGCPN. Pressurized intraperitoneal aerosol chemotherapy (PIPAC) and electrostatic PIPAC (ePIPAC) with paclitaxel in patients with peritoneal carcinomatosis. *ClinicalTrials.gov* 2022;(Bethesda (MD): National Library of Medicine (US)). <https://clinicaltrials.gov/study/NCT05395910?term=%20NCT05395910&rank=1&tab=table>.